Compounds > n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine
Page last updated: 2024-09-03

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and ldc4297

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with ldc4297 in 1 studies

Compound Research Comparison

Studies
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)		Trials
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)		Recent Studies (post-2010)
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)		Studies
(ldc4297)		Trials
(ldc4297)		Recent Studies (post-2010) (ldc4297)
79116808

Protein Interaction Comparison

ProteinTaxonomyn-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine (IC50)ldc4297 (IC50)
Cyclin-dependent kinase 1Homo sapiens (human)0.053
Cyclin-dependent kinase 2Homo sapiens (human)0.0064
Cyclin-dependent kinase 7Homo sapiens (human)0.0034
Cyclin-dependent kinase 9Homo sapiens (human)1.711

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1

Other Studies

1 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and ldc4297

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023